Literature DB >> 15519160

Synthesis and structure-activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives.

Hsu-Shan Huang1, Hui-Fen Chiu, An-Long Lee, Ching-Long Guo, Chun-Lung Yuan.   

Abstract

Anthraquinone-based compounds are attractive target for the design of new anticancer drugs. We have previously described a series of 1,5- and 1,4-difunctionalized anthraquinones, which exhibit different spectra of potency, together with human telomerase evaluation. The present study details the preparation of further, distinct series of regioisomeric difunctionalized amidoanthraquinone and examines their in vitro cytotoxicity in C6, Hepa G2, and 2.2.15 cell lines. Two structurally related compounds, mitoxantrone and adriamycin, were tested in parallel as positive controls. The structure-activity relationships indicated amido substitution may lead to a different mechanism of cytotoxicity. Compounds, which have -(CH2)n- side chains terminating in basic groups such as aminoalkyl-substituted, showed cytotoxic activity in several cell lines. The exact mode of intercalative binding may be dictated by the positional placement of substituent side chains. Implications for amidoanthraquinone cytotoxicity as potential anticancer agents are discussed. In addition, we further delineate the nature of the pharmacophore for this class of compounds, which provides a rational basis for the structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519160     DOI: 10.1016/j.bmc.2004.09.001

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  9,10-Dioxoanthracene-1,4-diyl bis-(4-methyl-benzene-sulfonate).

Authors:  Thapong Teerawatananond; Chiaranan Kerdsamut; Sirirat Kokpol; Nongnuj Muangsin
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-18

2.  In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Maryam Rachmawati Sumitra; Alexander T H Wu; Hsu-Shan Huang
Journal:  J Inflamm Res       Date:  2021-09-22

3.  Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Sung-Ling Tang; Feng-Cheng Liu; Alexander T H Wu; Hung-Yun Lin; Hsu-Shan Huang
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600

4.  New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules.

Authors:  Yu-Ru Lee; Dah-Shyong Yu; Ya-Chun Liang; Kuo-Feng Huang; Shih-Jie Chou; Tsung-Chih Chen; Chia-Chung Lee; Chun-Liang Chen; Shih-Hwa Chiou; Hsu-Shan Huang
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.